Clinical Hours: Mon-Fri, 8AM - 3PM(905) 493-5700
1885 Glenanna Road, Suite 220, Pickering, ON, L1V 6R6
Targeted biologic medications and advanced small molecule therapies for moderate to severe inflammatory skin conditions including psoriasis and atopic dermatitis.
Biologic therapies and advanced small molecule agents represent a significant advancement in the treatment of moderate to severe inflammatory skin conditions. Unlike traditional systemic medications that broadly suppress the immune system, these targeted therapies act on specific immune pathways involved in disease pathogenesis. This precision allows for improved efficacy while minimizing off-target effects.
Biologic therapies are protein-based medications derived from living cells. They are engineered to target specific components of the immune system, such as cytokines or cell-surface receptors, that drive inflammatory skin diseases. These medications are typically administered via subcutaneous injection or intravenous infusion at defined intervals.
By targeting specific immune pathways rather than broadly suppressing immunity, biologic therapies offer a more favourable safety profile compared to traditional immunosuppressive agents. The selective mechanism of action also contributes to higher response rates and more sustained disease control for many patients.
Biologic and advanced small molecule therapies are indicated for a range of moderate to severe inflammatory skin conditions. These include:
These therapies are generally considered when conventional treatments, such as topical agents and traditional systemic medications, have proven insufficient or are contraindicated.
Tumour necrosis factor-alpha (TNF-alpha) inhibitors were among the first biologic agents used in dermatology. These medications block the pro-inflammatory cytokine TNF-alpha, which plays a central role in the pathogenesis of psoriasis, psoriatic arthritis, and hidradenitis suppurativa. Examples include adalimumab, etanercept, and infliximab.
Interleukin-17 (IL-17) and interleukin-23 (IL-23) inhibitors target key cytokines in the IL-23/IL-17 axis, which is a primary driver of psoriatic disease. IL-17 inhibitors such as secukinumab and ixekizumab provide rapid and sustained clearance of psoriatic plaques. IL-23 inhibitors such as guselkumab, risankizumab, and tildrakizumab offer the advantage of less frequent dosing while maintaining high rates of disease control.
Dupilumab is a monoclonal antibody that inhibits interleukin-4 (IL-4) and interleukin-13 (IL-13) signalling, which are central mediators of type 2 inflammation in atopic dermatitis. It has demonstrated significant improvements in disease severity, itch, and quality of life for patients with moderate to severe atopic dermatitis.
Janus kinase (JAK) inhibitors represent a class of small molecule therapies that are administered orally. These agents block specific JAK enzymes involved in intracellular signalling pathways that drive inflammation. JAK inhibitors approved for dermatological indications include tofacitinib, upadacitinib, baricitinib, and abrocitinib.
JAK inhibitors offer the convenience of oral administration compared to injectable biologic agents. They have demonstrated efficacy in conditions such as atopic dermatitis, alopecia areata, and psoriasis. Selection of a specific JAK inhibitor is based on the condition being treated, patient factors, and the individual agent's safety profile.
Regular monitoring is an essential component of biologic and small molecule therapy. Baseline laboratory investigations, including complete blood count, liver function tests, hepatitis and tuberculosis screening, and other relevant studies, are performed prior to initiating treatment. Ongoing lab monitoring is conducted at defined intervals to ensure medication safety and detect any adverse effects early.
Treatment response is assessed at regular follow-up appointments using validated scoring systems such as the Psoriasis Area and Severity Index (PASI) or the Eczema Area and Severity Index (EASI). Adjustments to therapy, including dose modifications or switching to an alternative agent, may be made based on treatment response and tolerability.
Biologic therapies have accumulated extensive long-term safety data, with many agents demonstrating a favourable risk-benefit profile over years of continuous use. Common side effects may include injection site reactions and an increased susceptibility to certain infections. Serious adverse events are uncommon but are carefully monitored for through regular clinical and laboratory assessments.
JAK inhibitors carry specific considerations, including potential cardiovascular and thromboembolic risks that are evaluated on a patient-by-patient basis. Thorough pre-treatment screening and ongoing monitoring help mitigate these risks and ensure safe use of these agents.
At the Centre for Medical and Surgical Dermatology, Dr. Maksym Breslavets is experienced in the initiation and management of biologic and advanced small molecule therapies. A comprehensive approach is taken to identify the most appropriate targeted therapy for each patient, with ongoing monitoring to ensure optimal outcomes and medication safety.
Your feedback helps us improve our service information
The Centre for Medical and Surgical Dermatology provides comprehensive care across all areas of dermatology. To schedule a consultation with Dr. Breslavets, please obtain a referral from your healthcare provider.